Skip to Content

Research & Funding

Past CIP InitiativesRSS

This page lists past opportunities from CIP.

Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.

  • PAR-11-150: Quantitative Imaging for Evaluation of Responses to Cancer Therapies (U01)

    • Release Date: March 14, 2011
    • Application Receipt Date: Standard dates
    • Expiration Date: May 8, 2014
    • Contacts:

      Robert J. Nordstrom, Ph.D. (nordstrr@mail.nih.gov) at 240-276-5934

    The Cancer Imaging Program, (NCI), solicits applications to promote research on quantitative imaging of tumor response to cancer therapies in clinical trial settings, with the overall goal of facilitating clinical decision making. Proposed projects should include the appropriate development and adaptation/implementation of quantitative imaging methods, protocols and software solutions/tools (using existing commercial imaging platforms and instrumentation), and their application in current and planned Phase 1-2 clinical therapy trials. No support for the clinical trials, as such, will be provided under this initiative. The proposed projects must focus on imaging-derived quantitative measurements of responses to drugs and/or radiation therapy, and/or image-guided interventions. It is anticipated that these research goals will require multidisciplinary efforts. Therefore, this announcement solicits applications from multi-disciplinary teams to include oncologists as well as clinical and basic imaging scientists. The involvement of industrial partners in the development of the quantitative imaging methods is not required, but is strongly encouraged. Awardees form a Quantitative Imaging Network (QIN) to share ideas and approaches to validate and standardize imaging data and related imaging meta-data for quantitative measurements of responses to cancer therapies.

    See the CIP QIN website for a description of the program.

    • No set-aside

    See full description in NIH Guide: PAR-11-150

    Clarification of Scope and Requirements of PAR-11-150: NOT-CA-11-011

  • PA-10-080 and PA-10-079: Image-Guided Interventions (STTR [R41/R42] & SBIR [R43/R44])

    • Release Date: January 08, 2010
    • Application Receipt Date: Multiple dates, see announcements.
    • Expiration Date: January 8, 2013
    • Contacts:

      David Beylin, M.S., NCI, Phone: 301-496-0079, Email: beylind@mail.nih.gov
      Expires January 8, 2013

    These Funding Opportunity Announcements (FOA) support the development and clinical validation of systems for image-guided interventions (IGIs) for cancer. Specifically, the goals of this program are to provide support for: the development and optimization of fully integrated cancer imaging, monitoring, and therapy systems; the validation of integrated IGI systems through clinical evaluations; the development of multiple prototype integrated IGI systems as required for multisite clinical evaluations; and partnerships among small business, large business, and academic clinical centers, as well as small business joint ventures, in order to reach the research goals..

    See full description in NIH Guide: STTR (R41/R42) PA-10-080; SBIR (R43/44) PA-10-079

  • PA-09-253: Image-guided Drug Delivery in Cancer (R01)

    • Release Date: August 13, 2009
    • Application Receipt Date: Standard dates
    • Expiration Date: May 8, 2013
    • Contacts:

      Contact: Keyvan Farahani, Ph.D. (farahank@mail.nih.gov) at 240-276-5921

    The NCI encourages innovative translational research in the development of quantitative in vivo imaging characterization of image-guided drug delivery (IGDD) in cancer, including characterizations of the target, delivery validation, and therapy response. This initiative will support research in development of integrated imaging-based platforms for multifunctional and multiplexed drug delivery systems in cancer. Validation studies in non-human primates or large animal models and first in human studies directed towards translation of IGDD technology into the clinic will be considered appropriate for this initiative.

    • No set-aside

    See full description in NIH Guide: PA-09-253